David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B drug pricing program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.
Latest from David Wild
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
Cell and gene therapy is shifting into a new phase, as maturing commercial launches, rising big pharma participation and regulatory momentum replace hype and skepticism.
Senti Bio CEO Tim Lu explains how logic-gated CAR-NK therapy SENTI-202 distinguishes cancer from healthy cells in AML, achieving 50% response rates with favorable safety.
The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.
Scrip senior editor Jessica Merrill, Scrip US managing editor Mandy Jackson and In Vivo senior reporter David Wild discuss trends and topics from interviews and presentations at the J.P. Morgan Healthcare Conference and Biotech Showcase.
Biogen’s head of development reflects on transforming company strategy, surviving the Aduhelm crisis and building sustainable growth through disciplined portfolio management.